These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

437 related items for PubMed ID: 15788643

  • 1. Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease.
    Berruti A, Mosca A, Tucci M, Terrone C, Torta M, Tarabuzzi R, Russo L, Cracco C, Bollito E, Scarpa RM, Angeli A, Dogliotti L.
    Endocr Relat Cancer; 2005 Mar; 12(1):109-17. PubMed ID: 15788643
    [Abstract] [Full Text] [Related]

  • 2. [Plasma chromogranin-A (CgA)--a potential marker for diagnosis, monitoring and management of prostate cancer patients].
    Leibovitch I, Pinthus Y, Sella BA, Ramon J.
    Harefuah; 2006 Jan; 145(1):25-9, 78. PubMed ID: 16450720
    [Abstract] [Full Text] [Related]

  • 3. Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study.
    Taplin ME, George DJ, Halabi S, Sanford B, Febbo PG, Hennessy KT, Mihos CG, Vogelzang NJ, Small EJ, Kantoff PW.
    Urology; 2005 Aug; 66(2):386-91. PubMed ID: 16098367
    [Abstract] [Full Text] [Related]

  • 4. The prognostic value of serum chromogranin A and prostate specific antigen in prostate cancer patients for progression to the hormone resistance state.
    Zissimopoulos A, Bantis A, Sountoulides P, Giannakopoulos S, Kalaitzis C, Agelonidou E, Touloupidis S.
    Hell J Nucl Med; 2009 Aug; 12(3):234-7. PubMed ID: 19936334
    [Abstract] [Full Text] [Related]

  • 5. Insulin-like growth factor 1, chromogranin A and prostate specific antigen serum levels in prostate cancer patients and controls.
    Marszalek M, Wachter J, Ponholzer A, Leitha T, Rauchenwald M, Madersbacher S.
    Eur Urol; 2005 Jul; 48(1):34-9. PubMed ID: 15967249
    [Abstract] [Full Text] [Related]

  • 6. Oral estramustine therapy in serum chromogranin A-positive stage D3 prostate cancer patients.
    Zaky Ahel M, Kovacic K, Kraljic I, Tarle M.
    Anticancer Res; 2001 Jul; 21(2B):1475-9. PubMed ID: 11396235
    [Abstract] [Full Text] [Related]

  • 7. Prognostic significance of disordered calcium metabolism in hormone-refractory prostate cancer patients with metastatic bone disease.
    Tucci M, Mosca A, Lamanna G, Porpiglia F, Terzolo M, Vana F, Cracco C, Russo L, Gorzegno G, Tampellini M, Torta M, Reimondo G, Poggio M, Scarpa RM, Angeli A, Dogliotti L, Berruti A.
    Prostate Cancer Prostatic Dis; 2009 Jul; 12(1):94-9. PubMed ID: 18332901
    [Abstract] [Full Text] [Related]

  • 8. Effect of nonsteroidal antiandrogen monotherapy versus castration therapy on neuroendocrine differentiation in prostate carcinoma.
    Sciarra A, Di Silverio F.
    Urology; 2004 Mar; 63(3):523-7. PubMed ID: 15028450
    [Abstract] [Full Text] [Related]

  • 9. Circulating chromogranin a and hormone refractory prostate cancer chemotherapy.
    Cabrespine A, Guy L, Gachon F, Curé H, Chollet P, Bay JO.
    J Urol; 2006 Apr; 175(4):1347-52. PubMed ID: 16515996
    [Abstract] [Full Text] [Related]

  • 10. Chromogranin A expression in patients with hormone naïve prostate cancer predicts the development of hormone refractory disease.
    Berruti A, Mosca A, Porpiglia F, Bollito E, Tucci M, Vana F, Cracco C, Torta M, Russo L, Cappia S, Saini A, Angeli A, Papotti M, Scarpa RM, Dogliotti L.
    J Urol; 2007 Sep; 178(3 Pt 1):838-43; quiz 1129. PubMed ID: 17631319
    [Abstract] [Full Text] [Related]

  • 11. Variation in chromogranin A serum levels during intermittent versus continuous androgen deprivation therapy for prostate adenocarcinoma.
    Sciarra A, Monti S, Gentile V, Mariotti G, Cardi A, Voria G, Lucera R, Di Silverio F.
    Prostate; 2003 May 15; 55(3):168-79. PubMed ID: 12692782
    [Abstract] [Full Text] [Related]

  • 12. Prognostic value of serum markers for prostate cancer.
    Stenman UH, Abrahamsson PA, Aus G, Lilja H, Bangma C, Hamdy FC, Boccon-Gibod L, Ekman P.
    Scand J Urol Nephrol Suppl; 2005 May 15; (216):64-81. PubMed ID: 16019759
    [Abstract] [Full Text] [Related]

  • 13. Higher prostate-specific antigen levels predict improved survival in patients with hormone-refractory prostate cancer who have skeletal metastases and normal serum alkaline phosphatase.
    Xie W, Nakabayashi M, Regan MM, Oh WK.
    Cancer; 2007 Dec 15; 110(12):2709-15. PubMed ID: 17960608
    [Abstract] [Full Text] [Related]

  • 14. Chromogranin A and biochemical progression-free survival in prostate adenocarcinomas submitted to radical prostatectomy.
    Alessandro S, Vincenzo G, Maria AG, Stefano S, Alessandro G, Salvatore M, Vincenzo T, Franco DS.
    Endocr Relat Cancer; 2007 Sep 15; 14(3):625-32. PubMed ID: 17914093
    [Abstract] [Full Text] [Related]

  • 15. The prognostic role of immunohistochemical chromogranin a expression in prostate cancer patients is significantly modified by androgen-deprivation therapy.
    Berruti A, Bollito E, Cracco CM, Volante M, Ciccone G, Porpiglia F, Papotti M, Scarpa RM, Dogliotti L.
    Prostate; 2010 May 15; 70(7):718-26. PubMed ID: 20087896
    [Abstract] [Full Text] [Related]

  • 16. Acquired neuroendocrine-positivity during maximal androgen blockade in prostate cancer patients.
    Tarle M, Ahel MZ, Kovacić K.
    Anticancer Res; 2002 May 15; 22(4):2525-9. PubMed ID: 12174956
    [Abstract] [Full Text] [Related]

  • 17. Serum interleukin 6 as a prognostic factor in patients with prostate cancer.
    Nakashima J, Tachibana M, Horiguchi Y, Oya M, Ohigashi T, Asakura H, Murai M.
    Clin Cancer Res; 2000 Jul 15; 6(7):2702-6. PubMed ID: 10914713
    [Abstract] [Full Text] [Related]

  • 18. Prostate-specific antigen/prostatic acid phosphatase ratio is significant prognostic factor in patients with stage IV prostate cancer.
    Saito T, Hara N, Kitamura Y, Komatsubara S.
    Urology; 2007 Oct 15; 70(4):702-5. PubMed ID: 17991541
    [Abstract] [Full Text] [Related]

  • 19. Changes in chromogranin a serum levels during endocrine therapy in metastatic prostate cancer patients.
    Sasaki T, Komiya A, Suzuki H, Shimbo M, Ueda T, Akakura K, Ichikawa T.
    Eur Urol; 2005 Aug 15; 48(2):224-9; discussion 229-30. PubMed ID: 16005374
    [Abstract] [Full Text] [Related]

  • 20. Clinical understaging in patients with prostate adenocarcinoma submitted to radical prostatectomy: predictive value of serum chromogranin A.
    Sciarra A, Voria G, Monti S, Mazzone L, Mariotti G, Pozza M, D'Eramo G, Silverio FD.
    Prostate; 2004 Mar 01; 58(4):421-8. PubMed ID: 14968443
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.